Long-term clinical outcomes of prophylaxis with an rFVIIIFc or rFIXFc in adults aged ≥50 years with hemophilia A or B.

Autor: Quon D; Orthopaedic Hemophilia Treatment Center, Luskin Orthopaedic Institute for Children, Los Angeles, CA., Jackson S; Providence Health Care, St. Paul's Hospital, Vancouver, BC, Canada., Alvarez-Román MT; Department of Hematology, University Hospital La Paz, Madrid, Spain., Khan U; Sanofi, Cambridge, MA., Casiano S; Sanofi, Cambridge, MA., Ragni MV; Division of Hematology/Oncology, University of Pittsburgh Medical Center, Pittsburgh, PA., Rangarajan S; Faculty of Medicine, University of Southampton, Southampton, United Kingdom.
Jazyk: angličtina
Zdroj: Blood advances [Blood Adv] 2024 Sep 24; Vol. 8 (18), pp. 4751-4755.
DOI: 10.1182/bloodadvances.2023012462
Databáze: MEDLINE